New antifungal agents for the treatment of candidaemia

Area of Science:

• Medical Mycology
• Infectious Diseases
• Pharmacology

Background:

• Invasive candidiasis is a significant cause of mortality, necessitating prompt antifungal treatment.
• Current prediction models lead to overuse of antifungal drugs, increasing unnecessary patient treatment.
• Fluconazole resistance is low in Europe, yet low doses are frequently used.

Purpose of the Study:

• To review the characteristics of newer antifungal agents for treating candidemia.
• To emphasize the importance of judicious antifungal drug selection, dosing, and duration.
• To highlight the role of early microbiological data and medical education in optimizing antifungal therapy.

Main Methods:

• Literature review of new antifungals for candidemia treatment.
• Analysis of current practices in antifungal drug application and stewardship.
• Discussion of factors influencing antifungal drug choice, dose, route, and duration.

Main Results:

• Newer antifungals offer specific advantages, but their use requires careful case-by-case evaluation.
• Candins are fungicidal, effective against device-related infections, and well-tolerated with few interactions.
• Optimizing antifungal therapy involves balancing drug efficacy, cost, and patient-specific factors.

Conclusions:

• Judicious use of antifungals, informed by early microbiological data and education, is essential for managing invasive candidiasis.
• Antifungal stewardship programs should focus on appropriate drug selection, dosing, administration route, and therapy length.
• Balancing the benefits of newer, expensive antifungals against established therapies is critical for patient survival and resource management.